About Obsidian Therapeutics
Obsidian Therapeutics is a clinical-stage biotechnology company pioneering engineered tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor malignancies. The company's proprietary cytoDRiVE® platform uses drug-responsive domains to enable tunable control of therapeutic protein expression, with its lead program OBX-115 in clinical trials for advanced melanoma and non-small cell lung cancer.
Company details
Funding
Total raised
$325M
Last stage
Series C
Investors
Founders
Tariq Kassum
Co-founder of Obsidian Therapeutics; formerly held leadership roles at Takeda and Millennium Pharmaceuticals.
Vipin Suri
Co-founder of Obsidian Therapeutics; formerly held roles at Raze Therapeutics and GSK.
Thomas Wandless
Professor of Chemical and Systems Biology at Stanford University; pioneered the destabilizing domain technology that underpins Obsidian's cytoDRiVE platform.
Michael Gilman
Serial biotech entrepreneur and Ph.D. scientist; founding CEO of Padlock Therapeutics and Stromedix; former executive at Biogen and ARIAD Pharmaceuticals.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.